about
Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518).Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.PPAR-gamma activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancerOverview of the clinical efficacy of investigational anticancer drugs.Advances in molecular therapies in patients with brain tumors.IQGAP3 promotes EGFR-ERK signaling and the growth and metastasis of lung cancer cells.Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapiesUpdate on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?High predictive value of epidermal growth factor receptor phosphorylation but not of EGFRvIII mutation in resected stage I non-small cell lung cancer (NSCLC)Therapeutic targeting of receptor tyrosine kinases in lung cancer.Erlotinib resistance in lung cancer: current progress and future perspectives.ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours.Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.HtrA serine proteases as potential therapeutic targets in cancer.Harnessing of Programmed Necrosis for Fighting against Cancers.Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.EGFR inhibitor C225 increases the radiosensitivity of human lung squamous cancer cells.Celecoxib induces cell death on non-small cell lung cancer cells through endoplasmic reticulum stress.Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02.Prognostic values of ERK1/2 and p-ERK1/2 expressions for poor survival in non-small cell lung cancer.MAGE3 and Survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer.
P2860
Q33242719-19856B0D-8D12-4AF9-BE13-5E5D4ADF404EQ34003141-DB40260F-1738-48B1-A643-1C99125F29EDQ34768343-51EDC575-5C44-422D-8364-7B320377A6A8Q35067125-E18A8201-C630-4CA5-89BF-8C77DA193147Q35113656-5622E3AE-AA83-4EF5-99C7-4A8B9C36A442Q35172160-17157F96-CBAE-4F8D-83C4-B7616AFAA91FQ35549063-9BF053C7-EC4E-4C2B-B862-79C67047A1C1Q35667802-0AB44685-C4D1-4E6C-8DE1-595BA3FDBF5FQ35769805-1BD6B3F2-DAE6-4FB1-A3DF-480AE70367EDQ36158717-532D2AFA-2575-45CE-9971-9D8C40E2A11BQ36605522-E7745049-CEEF-41E6-9B43-73B4FA6EE3A9Q36694670-627AC8AC-0129-4929-AE10-3EE1C728C6B7Q37096361-5A1C8A6C-6927-4730-B2D9-FEC25507E851Q37515512-32F0D186-6A18-4DDA-BA79-B31BD631BB70Q38227878-B9E4CD12-07CC-4098-991F-07BB8EF65FBAQ39896250-531F1A2B-5A32-4D8F-920C-0074D94D8F5BQ42382736-BDA5DFAF-55E3-47CE-90DB-268DDE282203Q49304587-06B72236-B2E3-46F1-9D3D-A8F47D5AE7F7Q49501093-6959AC1E-FDA9-4B65-A332-36BAE1DB0D7CQ51666148-00D07C24-0BCE-437D-BAF6-42D2306B7F71Q54946747-FA82CB30-35DF-4145-86D2-883573CB1F26
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Novel targets for lung cancer therapy: part I.
@ast
Novel targets for lung cancer therapy: part I.
@en
Novel targets for lung cancer therapy: part I.
@nl
type
label
Novel targets for lung cancer therapy: part I.
@ast
Novel targets for lung cancer therapy: part I.
@en
Novel targets for lung cancer therapy: part I.
@nl
prefLabel
Novel targets for lung cancer therapy: part I.
@ast
Novel targets for lung cancer therapy: part I.
@en
Novel targets for lung cancer therapy: part I.
@nl
P356
P1476
Novel targets for lung cancer therapy: part I.
@en
P2093
Alex A Adjei
Grace K Dy
P304
P356
10.1200/JCO.2002.11.145
P407
P577
2002-06-01T00:00:00Z